Abstract 435TiP
Background
Treatment with PD-L1 or PD-1 targeting antibodies is a cornerstone in cancer therapy, but not all patients benefit from these drugs. For most indications, the current reference biomarker is PD-L1 expression in a tumor biopsy, but this method has several disadvantages. Molecular imaging, such as PET/CT using receptor-specific radiotracers, offers non-invasive, real-time visualization of treatment targets. Previous trials have explored a few PD-L1/PD-1 radiotracers but lacked a systematic approach focused on a single tumor type and standardized clinical management.
Trial design
The MIMIR-trial (EU CT 2022-500808-21-00, NCT05742269) involves newly diagnosed mTNBC patients planned for first-line systemic treatment. Participants undergo a PD-L1 PET/CT scan with [89Zr]Zr-atezolizumab followed by a biopsy, with results guiding subsequent treatment with chemotherapy (carboplatin and nab-paclitaxel), combined with atezolizumab based on PD-L1 status as determined by IHC and/or PET. Treatment effectiveness is assessed bi-monthly, and therapy is continued until disease progression or unmanageable toxicity. The primary aim is to determine the statistical concordance (Cohen’s kappa coefficient) between PD-L1 status by PET and IHC. To target a kappa of 0.80 with a precision of +/- 0.15, 64 patients are required in this study. Secondary objectives include evaluating the predictive value of PD-L1 PET for treatment response and development of immunotherapy-mediated toxicity. Tissue, feces, and blood samples are collected for further translational analysis. The trial is ongoing at Karolinska University Hospital in Stockholm, Sweden, with three patients enrolled so far. An additional cohort of patients with non small cell lung cancer will be opened during Q3-4 2024.
Clinical trial identification
EU CT 2022-500808-21-00, NCT05742269.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University hospital, Region Stockholm, Sweden.
Funding
Roche Sweden AB.
Disclosure
J. Bergh: Non-Financial Interests, Personal, Advisory Board: stratipath. All other authors have declared no conflicts of interest.
Resources from the same session
434TiP - ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Presenter: Yanchun Meng
Session: Poster session 15
436TiP - DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
Presenter: Joyce O'Shaughnessy
Session: Poster session 15
437TiP - An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
Presenter: Mridula George
Session: Poster session 15
439TiP - AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors
Presenter: Afshin Dowlati
Session: Poster session 15
517P - Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study
Presenter: Aziz Zaanan
Session: Poster session 15
520P - Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Presenter: Rocio Garcia-Carbonero
Session: Poster session 15
521P - XELOX +bev +tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
Presenter: Kai Ou
Session: Poster session 15